Improving HIV prevention strategies for pregnant and breastfeeding women in Malawi
Project 1 - Surveillance and monitoring systems to identify strategies to improve perinatal practices [Parent Title: PREVENTING INFANT INFECTIONS WITH IMPLEMENTATION SCIENCE IN MALAWI]
This study is looking at how a new HIV prevention method, called Cabotegravir, can help pregnant and breastfeeding women in Malawi stay healthy and avoid getting HIV, while also making sure they get the support they need during this important time.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11063847 on NIH RePORTER |
What this research studies
This research focuses on enhancing antenatal care strategies to prevent new HIV infections among pregnant and breastfeeding women in sub-Saharan Africa, particularly Malawi. It investigates the use of pre-exposure prophylaxis (PrEP), specifically the long-acting injectable Cabotegravir, to reduce HIV acquisition in this vulnerable population. The study aims to address implementation challenges such as poor adherence and follow-up, ensuring that women receive effective HIV prevention during pregnancy and breastfeeding. By gathering safety data on new PrEP options, the research seeks to inform national programs and improve health outcomes for mothers and infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant and breastfeeding women in sub-Saharan Africa who are at risk of HIV infection.
Not a fit: Patients who are not pregnant or breastfeeding, or those who are already living with HIV, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the rates of new HIV infections among pregnant and breastfeeding women, ultimately preventing mother-to-child transmission.
How similar studies have performed: Previous research has shown promise in using PrEP for HIV prevention, but this specific approach with long-acting injectable options is relatively novel.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Saidi, Friday — Univ of North Carolina Chapel Hill
- Study coordinator: Saidi, Friday
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.